| Stephen Christopher Hoffelt, MD | |
|
400 Ne Mother Joseph Pl, Vancouver, WA 98664-3200 | |
| (360) 514-1900 | |
| Not Available |
| Full Name | Stephen Christopher Hoffelt |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 26 Years |
| Location | 400 Ne Mother Joseph Pl, Vancouver, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194747733 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | MD26337 (Oregon) | Secondary |
| 2085R0001X | Radiology - Radiation Oncology | MD00045874 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Northwest | 5799688230 | 1482 |
News Archive
A new £1.1 million study led by the University of Stirling is seeking to understand recent changes in opening hours for bars and nightclubs, and how these changes impact on health, crime levels, and emergency services in Scotland.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ), and the leading supplier of heparin sodium to the U.S. market, announced today its continued support of the US Food & Drug Administration (FDA) and medical community for the October 1, 2009 implementation of the new United States Pharmacopeia (USP) monograph change for unfractionated heparin.
If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
A new £1.1 million study led by the University of Stirling is seeking to understand recent changes in opening hours for bars and nightclubs, and how these changes impact on health, crime levels, and emergency services in Scotland.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ), and the leading supplier of heparin sodium to the U.S. market, announced today its continued support of the US Food & Drug Administration (FDA) and medical community for the October 1, 2009 implementation of the new United States Pharmacopeia (USP) monograph change for unfractionated heparin.
If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Christopher Hoffelt, MD 3229 Ne Dunckley St, Portland, OR 97212-1735 Ph: (503) 750-9658 | Stephen Christopher Hoffelt, MD 400 Ne Mother Joseph Pl, Vancouver, WA 98664-3200 Ph: (360) 514-1900 |
News Archive
A new £1.1 million study led by the University of Stirling is seeking to understand recent changes in opening hours for bars and nightclubs, and how these changes impact on health, crime levels, and emergency services in Scotland.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ), and the leading supplier of heparin sodium to the U.S. market, announced today its continued support of the US Food & Drug Administration (FDA) and medical community for the October 1, 2009 implementation of the new United States Pharmacopeia (USP) monograph change for unfractionated heparin.
If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 1 days ago
Dr. Rebecca Gerber Kahn, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4816 Ne Thurston Way Ste A, Vancouver, WA 98662 Phone: 360-254-4914 Fax: 360-892-1533 | |
Dr. Aaron M Kaplan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave # 140, Vancouver, WA 98664 Phone: 360-882-2778 Fax: 360-604-1694 | |
Rod I. Belkin, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 4816a Ne Thurston Way, Vancouver, WA 98662 Phone: 360-254-4914 Fax: 360-449-4961 | |
Dr. Amar Yeshwant Purandare, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 400 Ne Mother Joseph Pl, Vancouver, WA 98664 Phone: 360-892-9664 | |
Faisal Amin Siddiqui, MD, PHD Radiology Medicare: Accepting Medicare Assignments Practice Location: 210 Se 136th Ave, Vancouver, WA 98684 Phone: 360-944-9889 | |
John Wr Schroeder, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4816a Ne Thurston Way, Vancouver, WA 98662 Phone: 360-254-4914 Fax: 360-449-4961 |